background
middl
east
respiratori
syndrom
coronaviru
merscov
caus
sever
respiratori
infect
high
mortal
rate
neutral
antibodi
target
spike
merscov
shown
therapeut
option
treatment
lethal
diseas
method
describ
germlin
divers
neutral
activ
potent
human
monoclon
antibodi
mab
target
merscov
spike
protein
biolog
function
assess
live
merscov
pseudotyp
particl
variant
structur
basi
also
determin
crystallograph
analysi
result
mab
display
strong
neutral
activ
merscov
two
immunoglobulin
heavychain
variabl
region
ighv
heavi
chain
name
show
potent
neutral
activ
pseudotyp
live
merscov
vitro
mutagenesi
analysi
suggest
recogn
distinct
region
glycoprotein
combin
mab
demonstr
synergist
effect
neutral
pseudotyp
merscov
structur
basi
neutral
recognit
reveal
epitop
almost
complet
overlap
receptorbind
site
conclus
data
provid
new
insight
specif
antibodi
repertoir
molecular
determin
neutral
natur
merscov
infect
human
find
support
addit
effort
design
develop
novel
therapi
combat
merscov
infect
human
ab
earli
stage
infect
still
capabl
potent
inhibitori
activ
howev
knowledg
human
neutral
mab
patient
natur
merscov
infect
provid
relev
detail
inform
due
limit
pan
strategi
number
mab
obtain
studi
describ
isol
character
human
mab
b
cell
infect
patient
sequenc
data
reveal
germlin
featur
specif
fulli
human
mab
target
merscov
protein
vitro
neutral
activ
two
potent
mab
select
determin
furthermor
structur
basi
neutral
merscov
also
explor
korean
businessman
expos
viru
guangdong
provinc
may
identifi
first
import
case
mer
infect
china
diagnosi
establish
reversetranscript
polymeras
chain
reaction
detect
complet
genom
sequenc
analysi
defin
convalesc
sera
peripher
blood
mononuclear
cell
collect
isol
patient
june
serum
ab
display
high
reactiv
merscov
protein
sino
biolog
inc
beij
china
neutral
activ
determin
enzymelink
immunosorb
assay
elisa
merscov
pseudoviru
product
neutral
assay
studi
human
sampl
obtain
approv
chines
center
diseas
control
prevent
institut
review
board
particip
provid
written
inform
consent
product
ab
base
specif
step
supplementari
materi
previou
method
experi
perform
describ
previous
interact
purifi
ab
merscov
protein
monitor
use
biolay
interferometri
bli
carri
singlecycl
mode
antihiggfc
immobil
serial
dilut
ab
micropl
accord
manufactur
protocol
protein
inject
sbind
respons
measur
appar
equilibrium
dissoci
constant
k
sab
interact
calcul
use
octet
softwar
pall
fortebio
first
label
biotin
afterward
ab
serial
dilut
halfmaxim
effect
concentr
ec
select
incub
ec
respons
two
mab
bind
protein
compar
infecti
merscov
conduct
within
approv
anim
biosafeti
laboratori
experiment
design
method
involv
challeng
live
merscov
isol
titrat
describ
previous
diffract
data
collect
beamlin
shanghai
synchrotron
research
facil
process
structur
determin
molecular
replac
crystallograph
softwar
phaser
iter
refin
program
phenix
model
build
program
coot
perform
complet
structur
refin
structur
valid
perform
program
procheck
structur
figur
gener
pymol
immunogenet
inform
system
imgt
use
immunogenet
analys
sequenc
align
made
clustalw
half
maxim
inhibitori
concentr
ic
calcul
ab
use
doserespons
inhibit
model
graphpad
prism
softwar
data
express
mean
standard
deviat
mean
standard
error
normal
data
set
test
use
anderson
darl
normal
test
synergist
addit
antagonist
interplay
ab
viru
neutral
evalu
median
effect
analysi
method
compusyn
softwar
combosyn
inc
provid
comprehens
view
human
mab
merscov
sought
isol
identifi
human
mab
target
merscov
protein
interest
determin
germlin
origin
gene
potent
neutral
ab
recov
patient
natur
merscov
infect
workflow
gener
human
mab
shown
figur
eightytwo
bcell
cultur
well
posit
protein
elisa
bcell
cultur
well
target
merscov
protein
show
potent
neutral
activ
inhibit
rate
ir
merscov
pseudoviru
figur
variabl
region
encod
heavi
light
chain
vh
vlvk
amplifi
except
potent
bcell
cultur
clone
express
vector
base
sequenc
immunogenet
analysi
expand
screen
ab
gene
sequenc
analyz
vh
plasmid
sequenc
found
distinct
vh
sequenc
origin
germlin
gene
figur
supplementari
tabl
sequenc
analyz
vl
plasmid
sequenc
found
distinct
vl
lambda
kappa
sequenc
origin
differ
germlin
gene
figur
supplementari
tabl
respect
note
major
famili
immunoglobulin
heavychain
variabl
region
ighv
germlin
percentag
respect
major
famili
immunoglobulin
lightchainkappachain
variabl
germlin
percentag
respect
among
neutral
activ
mab
gene
usag
domin
heavi
chain
wherea
gene
lambda
kappa
chain
use
highest
frequenc
light
chain
human
igg
repertoir
figur
variou
germlin
gene
frequenc
found
individu
bcell
well
robust
neutral
activ
merscov
pseudovirus
figur
remark
distinct
vh
sequenc
neutral
ab
gene
origin
germlin
gene
distinct
vl
sequenc
neutral
ab
gene
origin
differ
germlin
gene
tabl
supplementari
tabl
vh
segment
show
low
level
somat
hypermut
shm
rang
amino
acid
substitut
length
vh
complementaritydetermin
region
vh
vari
amino
acid
howev
vl
gene
divers
one
vl
use
kappa
chain
use
lambda
chain
supplementari
tabl
shm
rang
amino
acid
substitut
character
function
human
mab
target
merscov
protein
produc
mab
cell
cultur
larg
quantiti
differ
combin
vh
vlvk
gene
well
doubl
gene
express
vector
transient
transfect
human
embryon
kidney
hek
cell
ab
target
protein
step
step
step
step
step
step
step
cp
figur
workflow
gener
human
monoclon
antibodi
mab
clone
antibodi
gene
primari
human
b
cell
step
b
cell
isol
peripher
blood
mononuclear
cell
recov
middl
east
respiratori
syndrom
coronaviru
merscov
patient
cultur
plate
presenc
cell
human
interleukin
hil
day
step
cultur
supernat
use
detect
merscov
spike
merscov
bind
activ
use
enzymelink
immunosorb
assay
step
posit
well
use
detect
neutral
activ
merscov
pseudovirus
step
variabl
region
clone
express
vector
analyz
sequenc
technolog
step
select
vh
vlvk
clonal
gene
transient
cotransfect
cell
well
step
cultur
supernat
detect
merscov
pseudovirus
neutral
activ
step
neutral
mab
purifi
immunolog
function
valid
abbrevi
igh
immunoglobulin
heavychain
igl
immunoglobulin
light
chain
igk
immunoglobulin
ir
inhibit
rate
endoplasm
reticulum
membran
protein
complex
emc
strain
determin
elisa
wherea
mab
hemagglutin
influenza
viru
use
irrelev
ab
control
phosphatebuff
salin
use
blank
control
figur
among
mab
display
strong
bind
protein
mab
rang
mab
show
weak
bind
figur
neutral
activ
mab
test
cell
merscov
pseudoviru
variou
level
neutral
activ
detect
individu
mab
figur
c
neutral
activ
indic
ic
valu
mab
develop
studi
summar
figur
eleven
mab
display
strong
neutral
activ
merscov
pseudoviru
ic
valu
wherea
one
show
weak
neutral
activ
merscov
pseudoviru
ic
valu
ab
name
respect
demonstr
potent
neutral
activ
ic
valu
respect
merscov
pseudoviru
mab
share
vh
gene
neutral
activ
rather
differ
exampl
deriv
well
vh
germlin
gene
show
variou
level
neutral
activ
pair
differ
vl
ab
natur
present
patient
serum
supplementari
figur
character
bind
activ
bli
figur
neutral
activ
live
merscov
also
studi
figur
show
subnanomolar
affin
merscov
protein
k
equival
nm
respect
consist
k
equival
nm
neutral
activ
test
plaqu
reduct
neutral
test
use
live
merscov
stock
hcovemc
demonstr
potent
inhibitori
activ
merscov
infect
ic
respect
figur
determin
whether
mab
recogn
differ
epitop
label
two
ab
biotin
influenc
affin
ab
supplementari
figur
test
epitop
mab
biotin
ab
competit
elisa
figur
supplementari
tabl
thirteen
mab
could
divid
differ
group
base
bind
activ
high
medium
low
compet
abil
found
bind
epitop
protein
therefor
low
level
compet
activ
test
epitop
rang
neutral
activ
merscov
map
mutant
merscov
glycoprotein
figur
went
determin
whether
combin
two
mab
viru
neutral
synergist
addit
antagonist
shown
figur
constant
ratio
set
respect
ic
concentr
determin
figur
c
dosedepend
neutral
activ
combin
evalu
serial
dilut
concentr
time
ic
ic
figur
show
percentag
neutral
figur
left
fraction
effect
figur
middl
combin
index
ci
figur
right
use
compusyn
program
percentag
neutral
combin
approxim
reduct
ic
compar
alon
furthermor
ci
valu
combin
fraction
effect
valu
effect
dose
respect
ci
valu
indic
addit
effect
indic
synerg
indic
antagon
combin
clearli
strong
synerg
figur
right
show
logarithm
ci
scale
combin
demonstr
strong
synergist
effect
lower
higher
ab
concentr
elucid
molecular
mechan
merscov
neutral
reconstitut
complex
rbd
merscov
glycoprotein
fab
fragment
determin
crystal
structur
resolut
figur
previous
defin
merscov
rbd
two
subdomain
core
subdomain
compris
antiparallel
sheet
receptorbind
subdomain
compris
antiparallel
sheet
locat
core
subdomain
bind
receptorbind
subdomain
figur
use
total
residu
heavychain
complementar
determin
region
hcdr
loop
lightchain
complementar
determin
region
lcdr
interact
residu
strand
loop
loop
strand
loop
receptorbind
subdomain
supplementari
tabl
buri
surfac
contribut
heavi
chain
interfac
approxim
much
larger
approxim
buri
surfac
light
chain
core
bind
interfac
form
rbd
strand
hcdr
loop
figur
rbd
interact
ab
rbd
interact
ab
around
bind
core
rbd
form
hydrogenbond
interact
ab
light
chain
heavi
chain
respect
figur
superimposit
rbd
complex
structur
show
would
directli
compet
bind
receptor
figur
compar
footprint
rbd
also
found
rbd
residu
recogn
previous
shown
critic
bind
henc
bound
epitop
like
would
block
viral
attach
entri
studi
aim
comprehens
profil
human
bcell
respons
merscov
infect
use
recombin
protein
screen
b
cell
clone
extens
panel
anti
mab
peripher
b
cell
recov
merscov
patient
infect
korea
outbreak
success
demonstr
isol
verif
specif
human
mab
individu
natur
infect
merscov
found
antivir
ab
target
protein
merscov
use
divers
germlin
v
gene
origin
figur
supplementari
tabl
mab
demonstr
distinct
bind
activ
neutral
activ
mab
display
strong
neutral
activ
merscov
mab
heavi
chain
bound
differ
epitop
protein
show
potenc
largest
rang
neutral
activ
merscov
vitro
furthermor
identifi
structur
basic
neutral
recognit
crystallograph
analysi
reveal
epitop
almost
complet
overlap
receptorbind
site
compar
previou
report
human
mab
target
merscov
protein
tabl
result
show
high
divers
germlin
origin
gene
mab
recov
patient
natur
merscov
infect
cover
vh
germlin
gene
except
two
mab
scfvyeast
display
librari
immun
mice
also
found
sever
vh
germlin
gene
never
report
previou
human
mab
merscov
notabl
variou
genet
distinct
germlineencod
neutral
mab
exist
merscovrecov
patient
immun
repertoir
anoth
notic
featur
merscov
natur
infectionderiv
immun
repertoir
high
frequenc
allel
usag
suggest
germlin
gene
common
precursor
merscov
ab
might
recogn
similar
epitop
gene
also
preferenti
use
antivir
ab
includ
ab
human
immunodefici
viru
hiv
influenza
viru
hepat
c
viru
accordingli
vh
gene
mab
origin
low
shm
suggest
clone
aros
naiv
b
cell
pair
lambda
kappa
gene
respect
supplementari
tabl
germlin
natur
ab
impli
ab
could
elicit
rel
fast
low
number
shm
requir
affin
matur
contrast
ab
like
chronic
infect
could
highli
diverg
put
germlin
predecessor
may
requir
extens
complex
affin
matur
pathway
obtain
breadth
potenc
coronavirus
could
mutat
especi
crossspeci
transmiss
import
viru
adapt
new
host
receptor
similar
ribonucl
acid
virus
natur
variat
report
merscov
isol
second
mer
patient
qatar
given
viral
infect
neutral
escap
term
diverg
combin
immunotherapi
suggest
investig
cooper
potent
neutral
mab
crossneutr
protect
mab
result
indic
mab
present
divers
bind
phenotyp
compet
abil
suggest
diverg
epitop
mutagenesi
analysi
suggest
recogn
distinct
region
glycoprotein
work
would
requir
fine
map
epitop
futur
epitop
map
could
also
help
identifi
residu
critic
neutral
investig
viru
evolut
immun
pressur
forc
select
viru
mutat
addit
synergist
effect
also
found
use
combin
neutral
pseudotyp
merscov
provid
theoret
basi
combin
use
anim
clinic
test
futur
publish
human
merscovneutr
ab
target
site
rbd
spite
identifi
differ
ab
librari
pan
strategi
demonstr
rbd
domin
select
system
previous
determin
complex
structur
includ
rbd
bound
ab
respect
structur
comparison
rbd
complex
structur
show
major
orient
ab
bind
rbd
supplementari
figur
antibodi
adopt
first
orient
larg
amount
steric
clash
receptor
structur
superimposit
supplementari
figur
wherea
ab
tilt
first
orient
much
less
steric
clash
receptor
supplementari
figur
largest
overlap
epitop
supplementari
figur
pseudoviru
ic
valu
ml
lower
nm
ml
seem
extent
overlap
site
critic
neutral
capabl
ab
overal
result
ultrapot
human
neutral
ab
repertoir
provid
new
insight
merscovspecif
ab
induc
natur
infect
serolog
clonal
level
base
studi
effect
potent
neutral
ab
design
develop
treatment
human
case
merscov
infect
